Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01896999 (Clinical Trial/ Brentuximab vedotin/ SGN-035)

Study Title
Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01896999)

Trial Description
This phase I trial studies the side effects and best dose of ipilimumab when given together with brentuximab vedotin (also known as SGN-035) in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibodies, such as ipilimumab and brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread.

This trial is sponsored by The National Cancer Institute (NCI). [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 70
  • Start: January 2014
  • Estimated Primary Completion: March 2016 (Final data collection date for primary outcome measure)
  • Last verified: February 2015

Study Schematic

Screen Shot 2016-07-19 at 4.56.52 PM


Last Editorial review: July 25, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar